Chronic Myeloproliferative Disorders Completed Phase 2 Trials for Filgrastim (DB00099)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00006367Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With MyelofibrosisTreatment